Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19

Article Medicine, General & Internal

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Shruti Gupta et al.

Summary: A multicenter cohort study found that early treatment with tocilizumab may reduce mortality among critically ill patients with COVID-19. Further research from randomized clinical trials is needed to confirm these findings.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Jeroen J. A. van Kampen et al.

Summary: The study found that the median duration of shedding infectious virus in COVID-19 patients is 8 days, dropping below 5% after 15.2 days post onset of symptoms. High viral loads are associated with infectious SARS-CoV-2 isolation, while high serum neutralizing antibody titres are associated with non-infectious SARS-CoV-2.

NATURE COMMUNICATIONS (2021)

Add to Collection

Letter Respiratory System

Corticosteroids in COVID-19: one size does not fit all

Athena Gogali et al.

EUROPEAN RESPIRATORY JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection

F. Cogliati Dezza et al.

Summary: This study evaluated determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection and found that older age, albumin level, tocilizumab, and corticosteroid treatment were independently associated with late viral clearance.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Aziz Sheikh et al.

LANCET (2021)

Add to Collection

Article Immunology

Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine

Jinyoung Yang et al.

Summary: The study suggests that short-term corticosteroid use can reduce the reactogenicity of ChAd vaccine without compromising its immunogenicity. The ChAdPd group, taking corticosteroids around the time of vaccination, showed milder reactogenicity and a more robust cellular immune response compared to the ChAd and BNT groups without corticosteroid exposure.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study

Eun-Jeong Joo et al.

Summary: In patients with severe COVID-19, the remdesivir group exhibited lower MV requirement and better viral load reduction compared to supportive care, supporting the use of remdesivir in the treatment of severe COVID-19.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal